Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis

PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation

(2018) Xin Yao Qiu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations

(2018) Bryce Noll et al.   CANCER CYTOPATHOLOGY

SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma

(2018) Pierce K.H. Chow et al.   JOURNAL OF CLINICAL ONCOLOGY

AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation

(2018) Shirley Abitbol et al.   JOURNAL OF HEPATOLOGY

Dendritic Cells Pulsed with Exosomes in Combination with PD-1 Antibody Increase the Efficacy of Sorafenib in Hepatocellular Carcinoma Model

(2018) Shengbin Shi et al.   Translational Oncology

Prognostic significance of PD-L1 in solid tumor

(2017) Qianqian Wang et al.   MEDICINE

Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update

(2017) Masatoshi Kudo   ONCOLOGY

Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma

(2017) Xiaomeng Dai et al.   Translational Oncology

Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma

(2017) Hae Il Jung et al.   Cancer Research and Treatment

PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma

(2017) Kostandinos Sideras et al.   OncoImmunology

High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis

(2016) Fabian Finkelmeier et al.   EUROPEAN JOURNAL OF CANCER

Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features

(2016) Julien Calderaro et al.   HEPATOLOGY

CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia

(2016) Alexander Semaan et al.   VIRCHOWS ARCHIV

Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC

(2016) A. Gabrielson et al.   Cancer Immunology Research

PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma

(2016) Chang-Long Chen et al.   OncoImmunology

Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma

(2016) Qian-Kun Xie et al.   OncoImmunology

Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes

(2014) Ching-Yao Yang et al.   EUROPEAN JOURNAL OF CANCER

Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy

(2014) Yuichiroh Umemoto et al.   JOURNAL OF GASTROENTEROLOGY

Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma

(2014) Yun Wang et al.   TUMOR BIOLOGY

Does the Immune System Naturally Protect Against Cancer?

(2014) Alexandre Corthay   Frontiers in Immunology

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1

(2014) Yi-chi M. Kong et al.   Frontiers in Immunology

Endocrine Side Effects Induced by Immune Checkpoint Inhibitors

(2013) Salvatore Maria Corsello et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Programmed death ligand-1 expression in non-small cell lung cancer

(2013) Vamsidhar Velcheti et al.   LABORATORY INVESTIGATION

B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells

(2013) Sheng-Jia Shi et al.   PLoS One

B7 family checkpoint regulators in immune regulation and disease

(2013) Sabrina Ceeraz et al.   TRENDS IN IMMUNOLOGY

Re: Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer

(2012) Samir S. Taneja   JOURNAL OF UROLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Expression of B7-H1 protein in human pancreatic carcinoma tissues and its clinical significance

(2012) Xiao-Ling Chen et al.   Chinese Journal of Cancer

Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma

(2011) Zhen Zeng et al.   PLoS One

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

(2010) Ryosuke Hino et al.   CANCER

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

(2010) Chuan-Yong Mu et al.   MEDICAL ONCOLOGY

Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions

(2009) K. Wu et al.   CANCER RESEARCH

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

(2009) Q. Gao et al.   CLINICAL CANCER RESEARCH

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

(2009) Dong-Ming Kuang et al.   JOURNAL OF EXPERIMENTAL MEDICINE